The Overnight Picture

Two stories dominated overnight markets, and neither was about equities. The Strait of Hormuz — the narrow Persian Gulf chokepoint through which a significant share of the world's seaborne crude flows — saw tanker traffic grind to near zero following a fresh escalation between the United States and Iran. Tracking data showed only one tanker moving in the area, a dramatic collapse in traffic that immediately reverberated through commodity markets.

Goldman Sachs, which had previously projected an oil supply glut, reversed that call and flagged material supply disruption risk. That reversal carries weight: Goldman's prior glut thesis had been a ceiling on bullish oil sentiment for weeks. Removing it opens room for crude to reprice higher if the disruption persists.

In London, AZN (AstraZeneca) shed roughly 9% and approximately $27 billion in market capitalization after the company and partner IONS (Ionis Pharmaceuticals) disclosed that their jointly developed drug Wainua failed to outperform a placebo in a pivotal trial for ATTR-CM — transthyretin amyloid cardiomyopathy, a progressive disease in which abnormal protein deposits stiffen the heart muscle. A pivotal trial is the late-stage study regulators require before approving a drug for commercial use. Failure at this stage effectively closes the path to approval for that indication without starting over.

Theme 1: Hormuz and the Energy Repricing

The Hormuz disruption is the session's primary macro driver, and it demands a commodity-first read rather than an equity one.

The strait handles a large portion of global seaborne oil exports, including flows from Saudi Arabia, Iraq, Kuwait, and the UAE. A sustained closure — or even a credible threat of one — historically drives crude prices sharply higher and widens shipping insurance spreads. The current episode follows a trajectory that has been building across multiple sessions: U.S. strikes on Iran earlier this week triggered the initial oil rally, and Thursday's near-halt in tanker traffic represents an escalation of that same risk thread.

Goldman's forecast reversal is the institutional signal that matters most here. When a major bank publicly abandons a structural thesis — an oil glut — in response to a geopolitical event, it reshapes the framework other market participants use to price risk. Energy equities, oil futures, and LNG pricing are all likely to remain sensitive to any further diplomatic signals or transit data out of the region.

U.S. LNG exporters have already been benefiting from Middle East supply disruption. Earlier this week, Venture Global reported meaningfully higher liquefaction fees as buyers rerouted demand toward American suppliers. That dynamic could intensify if Hormuz remains effectively closed.

Theme 2: AstraZeneca's $27 Billion Clinical Setback

Drug trial failures are common. A $27 billion single-session loss is not.

The scale of AstraZeneca's decline reflects how much commercial value the market had assigned to Wainua's ATTR-CM indication. The disease has seen growing diagnosed prevalence in recent years, partly because improved imaging technology has made it easier to identify — meaning the addressable patient population was expanding even before Wainua had a clear path to approval. That combination of a large market and a late-stage asset made the drug a meaningful contributor to AstraZeneca's pipeline valuation.

For IONS, the setback is a blow to partnership revenue expectations. Ionis specializes in RNA-targeted medicines and had co-developed Wainua with AstraZeneca. No revised development path or alternative indication was immediately disclosed.

The failure also landed on the FTSE 100 like a weight, given AstraZeneca's status as one of the index's largest constituents. London investors were already navigating Hormuz-related energy volatility; the AstraZeneca news added a second, unrelated source of pressure to the session.

Theme 3: Apple-Broadcom and the Reshoring Chip Trade

Not everything this morning points downward. AAPL (Apple) signed a $30 billion supply agreement with Broadcom to manufacture chips in the United States, targeting production of more than 15 billion chips and the creation of hundreds of jobs.

The deal fits a pattern that has been building across the semiconductor industry: U.S. technology companies making large, visible commitments to domestic chip production, partly in response to policy incentives and partly to reduce supply chain concentration risk. Broadcom supplies Apple with wireless and networking chips used across iPhone and Mac product lines, so the agreement formalizes and extends an existing relationship rather than creating a new one.

For Broadcom, the $30 billion commitment provides long-term revenue visibility from one of the world's largest technology buyers — a meaningful anchor in an otherwise cyclical business. For Apple, it adds political cover in a trade environment where domestic investment pledges carry real weight.

The Calendar

The most important date on the near-term horizon is July 14, when JPM (JPMorgan Chase), BAC (Bank of America), C (Citigroup), and WFC (Wells Fargo) are all scheduled to report second-quarter earnings. The four reports together represent the unofficial start of U.S. earnings season and the Finance sector's first major read on net interest income — the spread banks earn between lending rates and deposit rates — loan demand, and credit quality in the current environment.

Bank of America has additional news in the mix: the bank passed recent regulatory stress tests and is reportedly pursuing an acquisition of Fiserv's debit payments network. How management frames that deal on the earnings call will draw scrutiny.

PEP (PepsiCo) has already reported, and the results were a soft data point for the consumer sector. The company missed analyst estimates, with North American consumers pulling back on branded food and beverage spending while international demand held up better. The miss adds early evidence that U.S. consumers — particularly middle and lower income brackets — are becoming more selective heading into a season where consumer staples companies will need to demonstrate pricing power without volume sacrifice.

No major Federal Reserve speakers or scheduled economic releases are flagged for Thursday's session in the current brief.

Watch List

Hormuz transit data is the single most important real-time signal today. A second consecutive session with near-zero tanker movement would reinforce Goldman's supply disruption thesis and likely push crude higher. Any diplomatic development — a ceasefire signal, an Iranian statement, or a U.S. de-escalation comment — could move energy markets sharply in either direction. President Trump's earlier ceasefire comments stabilized equity futures, but the situation remains fluid.

AstraZeneca's share price behavior through the London and U.S. sessions will indicate whether the $27 billion markdown was the market's complete repricing or whether further selling emerges as U.S. investors assess the pipeline implications. Watch whether IONS also continues to slide, as its RNA-targeted drug platform depends partly on partnership credibility.

For the consumer sector, watch whether other staples names begin to trade defensively ahead of their own reports, using PepsiCo's miss as a reference point. If the demand softness is sector-wide rather than company-specific, the read-through to retail sales data and broader consumer confidence becomes more significant.

Finally, July 14 bank earnings will set the tone for the broader earnings season. Any commentary on loan demand or credit quality in the context of current geopolitical uncertainty will be closely parsed — particularly given that energy price volatility can feed through to corporate borrowing costs and consumer confidence in ways that don't always show up immediately in headline numbers.